Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback